Table 1 Characteristics of patients in the training and validation cohorts.
Characteristics | Total (n = 304) | Training Cohort(n = 226) | Validation Cohort(n = 78) | p |
|---|---|---|---|---|
Demographics | ||||
Gender (Female) (n, %) | 91 (29.9%) | 69(30.5%) | 22 (28.2%) | 0.808 |
Age (years) | 82.0 (73.8,89.0) | 82.0 (74.0,89.0) | 83.5 (72.8,88.0) | 0.983 |
Weight (kg) | 60.0 (55.0,65.0) | 60.0 (55.0,65.0) | 60.0 (55.0,70.0) | 0.325 |
Infection types | ||||
Pneumonia (n, %) | 279 (91.8%) | 205 (90.7%) | 74 (94.9%) | 0.360 |
Blood stream infection (n, %) | 66 (21.7%) | 52 (23.0%) | 14 (17.9%) | 0.438 |
Abdominal infection (n, %) | 24 (7.89%) | 19 (8.41%) | 5 (6.41%) | 0.749 |
Urinary tract infection (n, %) | 62 (20.4%) | 45 (19.9%) | 17 (21.8%) | 0.847 |
Skin and soft tissue infection (n, %) | 32 (10.5%) | 25 (11.1%) | 7 (8.97%) | 0.761 |
Intracranial infection (n, %) | 13 (4.28%) | 9 (3.98%) | 4 (5.13%) | 0.746 |
Multiple infections (n, %) | 113 (37.2%) | 88 (38.9%) | 25 (32.1%) | 0.342 |
Comorbidities and complication | ||||
MODS (n, %) | 40 (13.2%) | 29 (12.8%) | 11 (14.1%) | 0.927 |
RF (n, %) | 161 (53.0%) | 122 (54.0%) | 39 (50.0%) | 0.634 |
Sepsis shock (n, %) | 72 (23.7%) | 54 (23.9%) | 18 (23.1%) | 1.000 |
Treatment regimens | ||||
Duration (days) | 8.0 (8.0,12.0) | 8.0 (8.0,12.0) | 8.0 (7.0,11.0) | 0.175 |
Concomitant antibiotics (n, %) | 273 (89.8%) | 205 (90.7%) | 68 (87.2%) | 0.502 |
Concomitant mannitol (n, %) | 33 (10.9%) | 24 (10.6%) | 9 (11.5%) | 0.989 |
Concentrations | ||||
Linezolid Cmin (mg/L) | 10.90 (6.42,17.20) | 10.90 (6.79,16.80) | 11.80 (6.18,18.60) | 0.888 |
PNU-142300 (mg/L) | 6.42 (3.06,10.50) | 5.54 (2.72,11.10) | 7.73 (4.39,9.64) | 0.147 |
Laboratory values | ||||
WBC (109/L) | 11.1 (7.35,16.70) | 11.6 (7.52,16.80) | 10.4 (6.30,14.50) | 0.082 |
Neutrophil (%) | 0.83 (0.73,0.91) | 0.84 (0.74,0.91) | 0.80 (0.73,0.87) | 0.066 |
Hemoglobin (g/L) | 89.0 (74.8,106.0) | 90.0 (76.2,108.0) | 87.0 (73.0,98.0) | 0.050 |
Platelet count (109/L) | 183 (133,253) | 187 (135,253) | 174 (124,252) | 0.471 |
CRP (mg/mL) | 73.7 (35.4,139.0) | 71.1 (31.8,132.0) | 83.5 (39.4,155.0) | 0.179 |
Procalcitonin (ng/mL) | 0.50 (0.17,2.08) | 0.52 (0.17,2.44) | 0.40 (0.17,1.10) | 0.070 |
Total bilirubin (µmol/L) | 8.73 (5.53,13.5) | 8.58 (4.79,13.4) | 9.60 (6.04,14.3) | 0.206 |
Albumin (g/L) | 31.7 (29.1,35.2) | 31.8 (29.2,35.2) | 31.6 (29.0,34.8) | 0.652 |
ALT (U/L) | 23.5 (15.0,44.0) | 24.0 (16.0,42.8) | 21.5 (12.0,47.8) | 0.400 |
Fibrinogen (g/L) | 4.30 (3.38,5.14) | 4.28 (3.32,5.17) | 4.34 (3.61,5.09) | 0.330 |
Creatinine (µmol/L) | 123.0 (84.8,209.0) | 118 (81.0,210.0) | 147 (99.3,203.0) | 0.158 |
CrCL (mL/min) | 35.4 (21.0,49.4) | 35.7 (21.2,49.7) | 32.0 (20.6,45.2) | 0.364 |
Incidence of linezolid-induced thrombocytopenia (n, %) | 105 (34.5%) | 76 (33.6%) | 29 (37.2%) | 0.667 |
